HomeAuthor Christina

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

STUART, Fla., Feb. 1, 2024 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer. With the appointment of Dr. Luchs, Robert Baratta, MD has stepped...

Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

STUART, Fla., Oct. 18, 2023 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“) today announced that it has entered into a license agreement with Glaukos Corporation (“Glaukos”) under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s proprietary ST-113 drug candidate for neuroprotection in glaucoma.  ST-113 is a patented pre-clinical asset that has demonstrated the ability...

Stuart Therapeutics Pty, Ltd Enters into Term Sheet with Radium Capital for the Financing of Anticipated Research and Development Tax Credits

Stuart Therapeutics Pty, Ltd is a newly formed, wholly owned subsidiary of Stuart Therapeutics, Inc. STUART, Fla., July 12, 2023 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced the formation of Stuart Therapeutics Pty,...

STUART, Fla., March 9, 2023 /PRNewswire/ — Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that it is sponsoring two research poster presentations by researchers at Vanderbilt University and the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO)...

Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.

STUART, Fla., Jan. 3, 2023 /PRNewswire/ — Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart’s clinical stage drug candidate ST-100. Under this agreement, AJU has the exclusive right to develop and commercialize ST-100 for South Korean and certain Southeast Asian markets in exchange for certain...

Stuart Therapeutics Announces Important Additions to the Company’s Intellectual Property Portfolio

Stuart Therapeutics Announces Important Additions to the Company’s Intellectual Property Portfolio  STUART, Fla., July 22, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical stage company developing advanced ophthalmic therapeutics, announced today that the United States Patent and Trademark office has issued a Notice of Allowance in each of two patent applications associated with the...

Stuart Therapeutics Announces Successful Outcome from Type C Meeting with FDA

STUART, Fla., July 18, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics, announced today the results of its Type C Guidance meeting with the U.S. Food and Drug Administration (FDA) regarding the continued development plan for ST-100, Stuart’s first drug candidate for the...

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100   – Achieved FDA Pre-Approved Single Primary Endpoint After 28 Days of Administration – Improvement in Total Ocular Discomfort after 14 Days   STUART, Fla., Jan. 3, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic...

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led...